Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Moderate to Severe Alzheimer's Disease
NCT05303701Phase 3Not yet recruiting
- Start
- Jul 2027
- Primary completion
- Jan 2028
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing GV1001 Placebo with GV1001 1.12 mg (2 arms). Primary endpoints: Severe Impairment Battery at 26 weeks and Clinician Interview-Based Impression of Change-Plus at 26 weeks. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05303701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303701.